TransMedics Group Inc. reported accelerating revenue growth, improved service margins, and increased market share in the U.S. in its recent quarter. The company raised its full-year revenue guidance to $764-774 million, expecting 24-26% organic growth and a 60% increase in service revenue year-over-year. Key growth drivers through 2027 include expansion into Europe, new heart and lung programs, and early-stage kidney opportunities. The updated 2028 price target is $129 per share, projecting a 46.5% upside and annual returns of 13-14%.
TransMedics Group Inc (TMDX) shares are currently priced at USD 93.79 on Pluang as of Nov 10, 2026, 17:51 WIB, showing no change in the last day. The stock trades between a 52-week low of USD 61.99 and a high of USD 150.42, reflecting notable volatility over the year. Pluang investors hold the stock for an average of 24 days, with buying activity at 80% compared to 20% selling.
